390,000 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Steadview Capital Management LLC

Steadview Capital Management LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 390,000 shares of the company’s stock, valued at approximately $19,442,000. Hims & Hers Health comprises about 2.8% of Steadview Capital Management LLC’s portfolio, making the stock its 9th biggest holding. Steadview Capital Management LLC owned approximately 0.17% of Hims & Hers Health as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth approximately $29,000. Bessemer Group Inc. boosted its stake in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Hims & Hers Health during the 1st quarter worth $30,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Hims & Hers Health during the first quarter worth $41,000. Finally, Larson Financial Group LLC raised its position in shares of Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after buying an additional 458 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Michael Chi sold 900 shares of Hims & Hers Health stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $58.25, for a total value of $52,425.00. Following the completion of the transaction, the insider owned 291,439 shares in the company, valued at $16,976,321.75. The trade was a 0.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock in a transaction on Friday, October 17th. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96. Following the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at approximately $4,012,354.16. This trade represents a 14.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 584,209 shares of company stock worth $31,837,916. Company insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent research reports. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Bank of America boosted their target price on Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday, November 4th. Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Finally, Truist Financial lowered their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $36.36 on Wednesday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company has a market cap of $8.28 billion, a P/E ratio of 67.33, a P/E/G ratio of 7.08 and a beta of 2.20. The stock has a 50-day moving average of $50.12 and a two-hundred day moving average of $51.42. Hims & Hers Health, Inc. has a 1-year low of $20.02 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.32 EPS. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has approved a stock buyback program on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 3% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.